| Company Name: |
Tianjin Kailiqi Biotechnology Co., Ltd.
|
| Tel: |
15076683720 |
| Email: |
klq@cw-bio.com |
| Products Intro: |
Product Name:T025
CAS:2407433-00-3
Purity:大于98% Package:1g,5g,10g,25g根据客户需要分装 Remarks:Not For Human Use, Lab Use Only.
|
|
| Product Name: | T-025 | | Synonyms: | T-025;T025,T-025;7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, N2-methyl-N4-(2-pyrimidinylmethyl)-5-(6-quinolinyl)-;N2-Methyl-N4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine | | CAS: | 2407433-00-3 | | MF: | C21H18N8 | | MW: | 382.42 | | EINECS: | | | Product Categories: | | | Mol File: | 2407433-00-3.mol |  |
| | T-025 Chemical Properties |
| density | 1.432±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 8.25 mg/mL (21.57 mM; Need ultrasonic) | | pka | 13.45±0.50(Predicted) |
| | T-025 Usage And Synthesis |
| Biological Activity | T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC50 values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research[1].
T025 (0-1000 nM; 72 hours) significantly suppresses the growth of MDA-MB-468 cells in a dose-dependent manner[1].T025 (0-1000 nM; 6 hours) reduces phosphorylation levels in MDA-MB-468 cells[1].
T025 (50 mg/kg; p.o.; 2, 4, 8 hours, Balb/c nude mice (7 to 8 week-old females).) suppress the CLK-dependent phosphorylation and induce skipping exon in various genes[1]. T025 (50 mg/kg; p.o.; twice daily on 2 days per week, for 3 weeks, Balb/c nude mice (7 to 8 week-old females).) inhibits MDA-MB-468 xenograft mice tumor growth and without affect body weight [1]. | | References | [1]. Iwai K, et al. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med. 2018 Jun;10(6):e8289. |
| | T-025 Preparation Products And Raw materials |
|